News & Updates
Filter by Specialty:
Second-line avelumab works against dMMR/MSI metastatic colorectal cancer
Treatment with the immune checkpoint inhibitor avelumab in the second-line setting confers survival and disease control benefits in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) when compared with standard treatment, with a favourable safety profile, according to the results of the phase II SAMCO-PRODIGE 54 trial.
Second-line avelumab works against dMMR/MSI metastatic colorectal cancer
09 Aug 2023
Uncomplicated UTI: Choosing antibiotics based on resistance rates helps prevent treatment failure
In the treatment of individuals with uncomplicated urinary tract infection (UTI), the use of antibiotics with lower reported resistance rates such as amoxicillin-clavulanate and nitrofurantoin (AC + N) lowers the rate of treatment failure, as shown in a study from Singapore.
Uncomplicated UTI: Choosing antibiotics based on resistance rates helps prevent treatment failure
08 Aug 2023
GLP-1 RA, with or without SGLT2 inhibitors, prevents cardiac events in T2D
Treatment with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) albiglutide results in fewer cardiovascular events, irrespective of sodium-glucose cotransporter-2 (SGLT2) inhibitor use, among patients with type 2 diabetes (T2D) and cardiovascular disease, according to the post hoc analysis of Harmony Outcomes*.
GLP-1 RA, with or without SGLT2 inhibitors, prevents cardiac events in T2D
08 Aug 2023
Glucocorticoid discontinuation may prevent infection in older RA patients
For older patients with rheumatoid arthritis (RA) who are receiving glucocorticoids (GCs), stopping its use lowers the incidence of infection, according to a study.
